-
1
-
-
85016493892
-
Impact of β-lactam antibiotic therapeutic drug monitoring on dose adjustments in critically ill patients undergoing continuous renal replacement therapy
-
Economou CJP, Wong G, McWhinney B et al. Impact of β-lactam antibiotic therapeutic drug monitoring on dose adjustments in critically ill patients undergoing continuous renal replacement therapy. Int J Antimicrob Agents 2017; 49: 589-94.
-
(2017)
Int J Antimicrob Agents
, vol.49
, pp. 589-594
-
-
Economou, C.J.P.1
Wong, G.2
McWhinney, B.3
-
2
-
-
84981156383
-
The ANTIBIOPERF study: a nationwide cross-sectional survey about practices for β-lactam administration and therapeutic drug monitoring among critically ill patients in France
-
Charmillon A, Novy E, Agrinier N et al. The ANTIBIOPERF study: a nationwide cross-sectional survey about practices for β-lactam administration and therapeutic drug monitoring among critically ill patients in France. Clin Microbiol Infect 2016; 22: 625-31.
-
(2016)
Clin Microbiol Infect
, vol.22
, pp. 625-631
-
-
Charmillon, A.1
Novy, E.2
Agrinier, N.3
-
3
-
-
84898474668
-
An international, multicentre survey of β-lactam antibiotic therapeutic drug monitoring practice in intensive care units
-
Wong G, Brinkman A, Benefield RJ et al. An international, multicentre survey of β-lactam antibiotic therapeutic drug monitoring practice in intensive care units. J Antimicrob Chemother 2014; 69: 1416-23.
-
(2014)
J Antimicrob Chemother
, vol.69
, pp. 1416-1423
-
-
Wong, G.1
Brinkman, A.2
Benefield, R.J.3
-
4
-
-
84963511132
-
Therapeutic drug monitoring of anti-infective agents in critically ill patients
-
Jager NG, van Hest RM, Lipman J et al. Therapeutic drug monitoring of anti-infective agents in critically ill patients. Expert Rev Clin Pharmacol 2016; 9: 961-79.
-
(2016)
Expert Rev Clin Pharmacol
, vol.9
, pp. 961-979
-
-
Jager, N.G.1
van Hest, R.M.2
Lipman, J.3
-
6
-
-
13244281964
-
Pharmacokinetic/pharmacodynamic modelling of antibacterials in vitro and in vivo using bacterial growth and kill kinetics: the minimum inhibitory concentration versus stationary concentration
-
Mouton JW, Vinks AA. Pharmacokinetic/pharmacodynamic modelling of antibacterials in vitro and in vivo using bacterial growth and kill kinetics: the minimum inhibitory concentration versus stationary concentration. Clin Pharmacokinet 2005; 44: 201-10.
-
(2005)
Clin Pharmacokinet
, vol.44
, pp. 201-210
-
-
Mouton, J.W.1
Vinks, A.A.2
-
7
-
-
0030009518
-
Dosage regimens of antibacterials. Implications of a pharmacokinetic/pharmacodynamic model
-
Bouvier d'Yvoire MJY, Maire PH. Dosage regimens of antibacterials. Implications of a pharmacokinetic/pharmacodynamic model. Clin Drug Investig 1996; 11: 229-39.
-
(1996)
Clin Drug Investig
, vol.11
, pp. 229-239
-
-
Bouvier d'Yvoire, M.J.Y.1
Maire, P.H.2
-
8
-
-
22244490051
-
Relationship between minimum inhibitory concentration and stationary concentration revisited: growth rates and minimum bactericidal concentrations
-
Mouton JW, Vinks AA. Relationship between minimum inhibitory concentration and stationary concentration revisited: growth rates and minimum bactericidal concentrations. Clin Pharmacokinet 2005; 44: 767-8.
-
(2005)
Clin Pharmacokinet
, vol.44
, pp. 767-768
-
-
Mouton, J.W.1
Vinks, A.A.2
-
9
-
-
85043341702
-
Linezolid susceptibility of glycopeptide-intermediately susceptible Staphylococcus aureus (GISA)-the Dutch experience
-
Abstract P1309. ESCMID, Basel, Switzerland
-
Voss A, Mouton JW, van Elzakker EPM et al. Linezolid susceptibility of glycopeptide-intermediately susceptible Staphylococcus aureus (GISA)-the Dutch experience. In: Abstracts of the Thirteenth European Congress of Clinical Microbiology and Infectious Diseases, Glasgow, UK, 2003. Abstract P1309. ESCMID, Basel, Switzerland.
-
Abstracts of the Thirteenth European Congress of Clinical Microbiology and Infectious Diseases, Glasgow, UK, 2003
-
-
Voss, A.1
Mouton, J.W.2
van Elzakker, E.P.M.3
-
11
-
-
0041527129
-
European harmonization of MIC breakpoints for antimicrobial susceptibility testing of bacteria
-
Kahlmeter G, Brown DF, Goldstein FW et al. European harmonization of MIC breakpoints for antimicrobial susceptibility testing of bacteria. JAntimicrobChemother 2003; 52: 145-8.
-
(2003)
JAntimicrobChemother
, vol.52
, pp. 145-148
-
-
Kahlmeter, G.1
Brown, D.F.2
Goldstein, F.W.3
-
12
-
-
84953418008
-
The 2014 Garrod Lecture: EUCAST-are we heading towards international agreement?
-
Kahlmeter G. The 2014 Garrod Lecture: EUCAST-are we heading towards international agreement? J Antimicrob Chemother 2015; 70: 2427-39.
-
(2015)
J Antimicrob Chemother
, vol.70
, pp. 2427-2439
-
-
Kahlmeter, G.1
-
13
-
-
0031952586
-
Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men
-
Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998; 26: 1-10; quiz 11-2.
-
(1998)
Clin Infect Dis
, vol.26
, pp. 1-12
-
-
Craig, W.A.1
-
14
-
-
33845696211
-
Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore
-
Ambrose PG, Bhavnani SM, Rubino CM et al. Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore. Clin Infect Dis 2007; 44: 79-86.
-
(2007)
Clin Infect Dis
, vol.44
, pp. 79-86
-
-
Ambrose, P.G.1
Bhavnani, S.M.2
Rubino, C.M.3
-
15
-
-
84964296722
-
Applying pharmacokinetic/ pharmacodynamic principles in critically ill patients: optimizing efficacy and reducing resistance development
-
Abdul-Aziz MH, Lipman J, Mouton JW et al. Applying pharmacokinetic/ pharmacodynamic principles in critically ill patients: optimizing efficacy and reducing resistance development. Semin Respir Crit Care Med 2015; 36: 136-53.
-
(2015)
Semin Respir Crit Care Med
, vol.36
, pp. 136-153
-
-
Abdul-Aziz, M.H.1
Lipman, J.2
Mouton, J.W.3
-
16
-
-
84901006498
-
Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions
-
Roberts JA, Abdul-Aziz MH, Lipman J et al. Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. Lancet Infect Dis 2014; 14: 498-509.
-
(2014)
Lancet Infect Dis
, vol.14
, pp. 498-509
-
-
Roberts, J.A.1
Abdul-Aziz, M.H.2
Lipman, J.3
-
17
-
-
72249093367
-
Augmented renal clearance: implications for antibacterial dosing in the critically ill
-
Udy AA, Roberts JA, Boots RJ et al. Augmented renal clearance: implications for antibacterial dosing in the critically ill. Clin Pharmacokinet 2010; 49: 1-16.
-
(2010)
Clin Pharmacokinet
, vol.49
, pp. 1-16
-
-
Udy, A.A.1
Roberts, J.A.2
Boots, R.J.3
-
18
-
-
69949103098
-
Evaluation of quinolones for use in detection of determinants of acquired quinolone resistance, including the newtransmissible resistance mechanisms qnrA, qnrB, qnrS, and aac(6')Ib-cr, in Escherichia coli and Salmonella enterica and determinations of wild-type distributions
-
Cavaco LM, Aarestrup FM. Evaluation of quinolones for use in detection of determinants of acquired quinolone resistance, including the newtransmissible resistance mechanisms qnrA, qnrB, qnrS, and aac(6')Ib-cr, in Escherichia coli and Salmonella enterica and determinations of wild-type distributions. J ClinMicrobiol 2009; 47: 2751-8.
-
(2009)
J ClinMicrobiol
, vol.47
, pp. 2751-2758
-
-
Cavaco, L.M.1
Aarestrup, F.M.2
-
19
-
-
68549132348
-
Cephalosporin MIC distribution of extended-spectrum-β-lactamase- and pAmpC-producing Escherichia coli and Klebsiella species
-
Kohner PC, Robberts FJ, Cockerill FR 3rd et al. Cephalosporin MIC distribution of extended-spectrum-β-lactamase- and pAmpC-producing Escherichia coli and Klebsiella species. J ClinMicrobiol 2009; 47: 2419-25.
-
(2009)
J ClinMicrobiol
, vol.47
, pp. 2419-2425
-
-
Kohner, P.C.1
Robberts, F.J.2
Cockerill, F.R.3
-
20
-
-
84945176706
-
Development of a pefloxacin disk diffusion method for detection of fluoroquinolone-resistant Salmonella enterica
-
Skov R, Matuschek E, Sjölund-Karlsson M et al. Development of a pefloxacin disk diffusion method for detection of fluoroquinolone-resistant Salmonella enterica. JClinMicrobiol 2015; 53: 3411-7.
-
(2015)
JClinMicrobiol
, vol.53
, pp. 3411-3417
-
-
Skov, R.1
Matuschek, E.2
Sjölund-Karlsson, M.3
-
21
-
-
85043325004
-
-
EUCAST. https://mic.eucast.org/Eucast2/.
-
-
-
-
22
-
-
67651083250
-
Vancomycin therapeutic guidelines: a summary of consensus recommendations from the Infectious Diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists
-
Rybak MJ, Lomaestro BM, Rotschafer JC et al. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the Infectious Diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis 2009; 49: 325-7.
-
(2009)
Clin Infect Dis
, vol.49
, pp. 325-327
-
-
Rybak, M.J.1
Lomaestro, B.M.2
Rotschafer, J.C.3
-
23
-
-
84949026642
-
Therapeutic drug monitoring of the β-lactamantibiotics: what is the evidence and which patients should we be using it for?
-
Huttner A, Harbarth S, Hope WW et al. Therapeutic drug monitoring of the β-lactamantibiotics: what is the evidence and which patients should we be using it for? J Antimicrob Chemother 2015; 70: 3178-83.
-
(2015)
J Antimicrob Chemother
, vol.70
, pp. 3178-3183
-
-
Huttner, A.1
Harbarth, S.2
Hope, W.W.3
-
24
-
-
0036736403
-
Pharmacodynamics of cefepime in patients with Gram-negative infections
-
Tam VH, McKinnon PS, Akins RL et al. Pharmacodynamics of cefepime in patients with Gram-negative infections. J Antimicrob Chemother 2002; 50: 425-8.
-
(2002)
J Antimicrob Chemother
, vol.50
, pp. 425-428
-
-
Tam, V.H.1
McKinnon, P.S.2
Akins, R.L.3
|